The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen
Open accessAbstract
Transferrin receptor (CD71) is involved in the cellular uptake of iron and is expressed on cells with high proliferation. It may be implicated in promoting the growth of endocrine resistant phenotypes within ER+/luminal-like breast cancer. We used a panel of in vitro cell models of acquired resistance to tamoxifen (TAMR), Faslodex (FASR) or severe oestrogen deprivation (MCF-7X) and the ER+ luminal MCF-7 parental line to determine CD71 mRNA expression and to study transferrin (Tf) effects on in vitro tumour growth and its inhibition. Furthermore, CD71 protein expression was assessed in a well-characterized series of patients with invasive breast carcinoma using tissue microarrays. Our results demonstrated a striking elevation of CD71 in all cell models of acquired resistance. Exogenous Tf significantly promoted growth in MCF-7-X and MCF-7 cells but more so in MCF-7-X; this growth was significantly reduced by Faslodex (FAS) or a phosphoinositide-3 kinase inhibitor (LY294002). Increased CD71 expression was associated with poor NPI score, tumour proliferation, basal CKs, p53, EGFR, HER2, steroid receptor negativity and shortened breast cancer specific survival (P < 0.001). On multivariate analysis, CD71 was found to be an independent prognostic factor in the ER+ cohort of patients. In conclusion, therapies of current interest in breast cancer (e.g. FAS, PI3K-inhibitors) appear able to partially impact on transferrin/CD71-promoted growth, but further investigation of this important mitogenic mechanism may assist in designing new therapeutic strategies to target highly proliferative, endocrine resistant breast cancers. CD71 appears to be a candidate marker of a subgroup of ER+/luminal-like breast cancer characterised by poor outcome and resistance to tamoxifen.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Upregulation of this highly conserved iron acquisition pathway is found in a variety of cancers, including breast and colon [90,91,92,93].”
From Iron as a central player and promising target in cancer progression (2019) · cites this paper as [91]
Citations
Cites
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
Elston, C. W., & Ellis, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,181
Self-citationRepeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R. J., Parker, J. S., Hastie, T. J., Marron, J. S., Nobel, A. B., Deng, S., Johnsen, H., Pesich, R., Geisler, S. B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,508
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Barlund, M. T., Schraml, P., Leighton, S. B., Torhorst, J. K. H., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,101
Sotiriou, C. P., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A. A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 2,024
Pathological prognostic factors in breast cancer
Elston, C. W. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00034-7 · Cited by 1,744
Predicting the clinical status of human breast cancer by using gene expression profiles
West, M., Blanchette, C., Dressman, H. K., Huang, E. S., Ishida, S., Spang, R., Zuzan, H., Olson, J. A., Marks, J. R., & Nevins, J. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201162998 · Cited by 1,318
The Nottingham prognostic index in primary breast cancer
Galea, M. H., Blamey, R. W., Elston, C. W., & Ellis, I. O. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01840834 · Cited by 1,078
Self-citationMcCarty, K. S., MILLER, L. S., Cox, E. B., Konrath, J. G., & McCarty, K. S. (1985) · PubMed · Cited by 1,027
Research works printed but not linked: 2
- Lanson B, Drenou B, Gueret P, Amiot L, Bernard M, Dauriac C et al (1997) Prognostic value of CD71 expression in mantle cell lymphoma. Exp Hematol 25:401
- Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874. doi: 10.1073/pnas.191367098 · DOI
Cited by
Sorted by citations
Iron and cancer: recent insights
Manz, D. H., Blanchette, N. L., Paul, B. T., Torti, F. M., & Torti, S. V. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13008 · Cited by 507
Torti, S. V., Manz, D. H., Paul, B. T., Blanchette-Farra, N., & Torti, F. M. (2018) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082117-051732 · Cited by 426
Transferrin receptor 1 in cancer: a new sight for cancer therapy.
Shen, Y., Li, X., Dong, D., Zhang, B., Xue, Y., & Shang, P. (2018) · Europe PMC (PubMed Central) · Cited by 357
Targeting iron metabolism in drug discovery and delivery
Crielaard, B. J., Lammers, T., & Rivella, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.248 · Cited by 352
Iron as a central player and promising target in cancer progression
Jung, M., Mertens, C., Tomat, E., & Brüne, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020273 · Cited by 268
Metadata
- Authors
- Habashy, H. O., Powe, D. G., Staka, C. M., Rakha, E. A., Ball, G., Green, A. R., Aleskandarany, M., Paish, E. C., Douglas Macmillan, R., Nicholson, R. I., Ellis, I. O., & Gee, J. M. W.
- Affiliations
- University of Nottingham (GB)
- Cardiff University (GB)
- Nottingham Trent University (GB)
- Corresponding author
- Ellis, Ian O.
- ORCID
- Venue
- Breast Cancer Research and Treatment
- Published
- 2009-02-24
- Volume
- 119
- Issue
- 2
- Pages
- 283-293
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2092206294
- Cited by
- 236
- References
- 44
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 10 · 2023: 20 · 2022: 15 · 2021: 24 · 2020: 19 · 2019: 26 · 2018: 11 · 2017: 20 · 2016: 17 · 2015: 8 · 2014: 10 · 2013: 8 · 2012: 13
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- green
- hal.science
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Nottingham Trent University's Institutional Repository (Nottingham Trent Repository) (submittedVersion)
- Trinity's Access to Research Output (TARA) (Trinity College Dublin) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Keywords
- transferrin receptor, breast cancer, tamoxifen resistance, endocrine therapy resistance, estrogen receptor-positive breast cancer, prognostic factors, transferrin, PI3K inhibitors, LY294002, fulvestrant, MCF-7 cells, tumour proliferation, breast cancer-specific survival, HER2, EGFR, p53
- MeSH terms
- Fulvestrant, Phosphoinositide-3 Kinase Inhibitors, Adult, Breast Neoplasms, Carcinoma, Chromones, Estradiol, Female, Flavonoids, Humans, Immunohistochemistry, Middle Aged, Morpholines, Neoplasm Invasiveness, Predictive Value of Tests, Receptors, Estrogen, Receptors, Transferrin, Retrospective Studies, RNA, Messenger, Tamoxifen, Time Factors, Transferrin, Biomarkers, Tumor, Antigens, CD, Gene Expression Regulation, Neoplastic, Proportional Hazards Models, Treatment Outcome, Risk Assessment, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Reverse Transcriptase Polymerase Chain Reaction, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Tissue Array Analysis, Protein Kinase Inhibitors, Cell Proliferation, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
